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ICAM-1 antisense oligodesoxynucleotides prevent reperfusion
injury and enhance immediate graft function in renal transplan-
tation.
Background. Ischemia-reperfusion injury after organ transplan-
tation is a major cause of delayed graft function. We showed
earlier that antisense oligodesoxynucleotides (ODN) for intercel-
lular adhesion molecule-1 (ICAM-1) ameliorate reperfusion in-
jury after acute ischemia. This study tested the hypothesis that
antisense ODN for ICAM-1 prevents ischemia-reperfusion injury
and facilitates immediate graft function in a rat autotransplanta-
tion model.
Methods. Both kidneys were removed from male Lewis rats and
re-implanted the left kidney after 30 minutes of cold ischemia
time. The warm ischemia time was 60 minutes. Sham operated,
uninephrectomized animals served as controls for renal function
and histology. ICAM-1 antisense ODN (5 mg/kg), reverse ODN,
or saline-vehicle were administered to donor animals i.v. six hours
before autotransplantation. Glomerular filtration rate (inulin
clearance), and serum creatinine concentrations were measured
24 hours post-transplantation. Tubular necrosis severity was as-
sessed by histological grading scale. ICAM-1 expression was
determined by immunohistochemistry and Western blot.
Results. Antisense ODN decreased ICAM-1 expression and
leukocyte infiltration significantly. Antisense ODN-treated ani-
mals showed significantly less tubular necrosis, than controls.
Serum creatinine of antisense ODN-treated animals (N 5 6) was
0.55 6 0.02 mg/dl compared to 1.92 6 0.07 mg/dl in reverse
ODN-treated controls (N 5 6; P , 0.01), 24 hours after trans-
plantation. Antisense ODN-treated animals had normal GFR
(0.93 6 0.07 ml/min/kidney wt) compared to sham-operated
animals (0.95 6 0.09 ml/min/kidney wt), while autotransplanted
animals treated with reverse ODN or saline-vehicle were all
anuric. The ischemia-reperfusion-induced up-regulation of MHC
class II was totally prevented by antisense ODN.
Conclusions. ICAM-1 inhibition ameliorates ischemia-reperfu-
sion injury and prevents delayed graft function. Antisense ODN-
treatment of donors or donor organs for ICAM-1 may be useful
for the prevention of reperfusion injury in human renal transplan-
tation.
The initial reperfusion of organ grafts with fresh blood
after storage and transport is a critical period in transplan-
tation. During reperfusion, a variety of mechanisms are
activated that may impair graft function above and beyond
the injury associated with ischemia itself [1, 2]. This so-
called ischemia-reperfusion injury includes the generation
of oxygen free radicals, recruitment and activation of
circulating inflammatory cells, and liberation of numerous
mediators acting both locally and systemically [3–6]. Alter-
ations in microvascular perfusion are particularly important
[7]. Ischemia-reperfusion injury is responsible for delayed
graft function, which may increase postoperative morbidity,
including the risk of early allograft rejection [8]. In cadav-
eric renal transplantation, postoperative delayed graft func-
tion is common and is associated with a less favorable
outcome [9]. Thus, immediate function is a primary goal in
renal transplantation [10].
Recent evidence indicates that leukocyte adhesion to the
endothelium plays an essential role in ischemia-reperfusion
injury [11, 12]. In the kidney, the adherent leukocytes plug
capillaries, generate proteolytic enzymes, and release cyto-
kines. The vasa recta become congested, capillary perfusion
is impaired [13], and endothelial permeability is increased
[14]. Increased adhesion also leads to oxygen free radical
generation and tissue infiltration by activated neutrophils
[15, 16]. Adhesion molecule-mediated neutrophil endothe-
lial binding is central to this process [17, 18].
Neutrophil adhesion involves b2 integrins, such as
CD11a/CD18 (lymphocyte function-associated antigen-1,
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or LFA-1), CD11b/CD18 (membrane attack complex-1, or
Mac-1), and CD11c/CD18 (p150,95), and their ligand
ICAM-1 [19–21]. Studies in liver, brain, myocardium, and
kidney [22–26] showed that ICAM-1 is up-regulated during
ischemia-reperfusion injury. Antibodies against either
CD11a/CD18 or ICAM-1 prevented tissue damage and
protected organ function in earlier studies [23, 27, 28].
Antibodies against both CD11/CD18, and ICAM-1, ame-
liorated ischemia-reperfusion injury and protected renal
function [29, 30]. However, antibody treatment has inher-
ent problems which could be circumvented with antisense
oligodesoxynucleotides (ODN). We recently used antisense
ODN to inhibit ICAM-1 expression in ischemic kidneys.
We demonstrated that neutrophil adhesion and infiltration
can be prevented and that ischemia-induced acute renal
failure can be ameliorated [22]. In the present study we
investigated the hypothesis that treatment with antisense
ODN for ICAM-1 can be used to pretreat the donor organ
[31], and thereby reduce delayed graft function. We dem-
onstrated that ICAM-1 plays an important role in reperfu-
sion injury after transplantation, that inhibition of ICAM-1
expression ameliorates tissue damage, and that antisense
ODN treatment prevents delayed graft function.
METHODS
Oligodesoxynucleotides
Phosphorothioate oligodesoxyribonucleotides (ODN)
were purchased (Tib Molbiol, Berlin, Germany). We se-
lected an antisense ODN (ISIS 1939) against the human 39
untranslated region derived from the rat ICAM sequence
RSICAM and the human ICAM-1 sequence HSICAM01
(European Molecular Biology Laboratories database, Hei-
delberg, Germany) [3, 32, 33]. For the rat experiments, we
compared rat and human sequence data and used the rat
homologue to ISIS 1939. The antisense sequence was 59
ACC GGA TAT CAC ACC TTC CT 39. The reverse sense
ODN sequence was used as control. We used a cationic
lipid solution (Lipofectin; GIBCO BRL, Life Technologies,
Hamburg, Germany) to enhance ODN uptake.
Surgical procedure and experimental groups
To investigate the influence of antisense ODN for
ICAM-1 on reperfusion injury during transplantation, we
used a Lewis rat autotransplantation model. Both kidneys
of normal Lewis rats were removed and the left kidney was
transplanted back after 30 minutes of cold ischemia time.
The animals were treated with antisense ODN for ICAM-1,
six hours prior to transplantation. Warm ischemia was
maintained at 60 minutes. After cold and warm ischemia,
the left kidneys were transplanted back into the Lewis rats.
Sham-operated, uninephrectomized animals were used to
define renal function in the uninephrectomized state.
These animals were compared to three autotransplanted
groups: autotransplanted saline-treated animals served as
“no treatment” controls; autotransplanted animals treated
with antisense ODN served as the “active treatment”
group; and, reverse ODN-treated autotransplanted animals
served as the “control treatment” group. Twenty-four hours
after transplantation, the renal function was assessed, the
animals were sacrificed, and the transplanted kidneys were
examined. A schematic outline of these experiments is
shown in Figure 1.
Renal transplantation was carried out according to a
modified protocol developed by Tullius et al [34, 35]. Male
Lewis (LEW, RT) rats (150 to 200 g) purchased from
Charles-River GmbH (Sulzfeld, Germany) were used in the
experiments [1]. The animals had free access to tap water
and standard rat diet (No. C-1000; Altromin, Lage, Ger-
many) and were kept under regular lighting conditions
(lights on at 06:00 and off at 18:00) at a constant temper-
ature 24°C. All procedures were approved by local author-
ities (Permit AZ IV.A4/5-G 0406/95) according to guide-
lines corresponding to the American Physiological Society.
The rats were fasted overnight before surgery. Animals
were primarily anesthetized intraperitoneally (i.p.) with
thiohexital (Brevimytal; Bayer, Leverkusen, Germany) at
1.5 ml/kg of body wt, and catheters were placed in the right
femoral artery and the right jugular vein. ODN (5 mg/kg
body wt) were administered intravenously (i.v.) in a 1 ml
solution containing a lipofectin-ODN mix or saline vehicle.
Fig. 1. Experimental protocol. Three
autotransplanted groups were studied: saline-
treated rats, antisense oligodesoxynucleotide
(ODN)-treated rats, and reverse ODN-treated
rats. Their renal function and histology was also
compared to uninephrectomized,
nonautotransplanted, sham-operated, control
rats. The time course is outlined.
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Animals were allowed to recover for six hours and then
were re-anesthetized with a 4% chloral hydrate solution
(250 mg/kg i.p.). They were placed on a heated surgical
table to maintain rectal temperature at 37°C. A long
midline abdominal incision was made, the intestine was
wrapped in isotonic saline moistened gauze, and placed on
the thorax in order to expose the aorta and inferior vena
cava together with the renal vessels. The left renal artery
and vein were separated from each other and their collat-
eral branches, adrenal artery and vein and spermatic artery
and vein, were double ligated with 7-0 silk and divided with
an electrocautery device. The ureter was freed from the
surrounding fibrotic tissue and cut in the closest proximity
to its ostium on the dorsal side of the bladder. Afterwards,
the kidney was freed from perirenal fat. Microaneurysm
clips were placed on the renal artery and the renal vein and
vessels were cut with an iris microscissors. Perfusion (ex
vivo) with 5 ml cold University of Wisconsin (UW) solution
followed. Finally, the kidney was placed in cold UW
solution (0 to 4°C) for 30 minutes. During this cold
ischemic interval, the abdominal incision was covered with
moistened gauze and parafilm. The anastomoses were
completed end-to-end, using 10-0 prolene suture material.
The anastomosis time averaged 30 minutes; clips were left
over the vessels an additional 30 minutes to produce an
extended warm ischemia time. Thus, the warm ischemic
time amounted to one hour. The ureter was placed into the
bladder through a small incision in the apex and its
surrounding connective tissue was fixed to the outer blad-
der wall with two, 9-0 ethilon stitches. The right nephrec-
tomy was performed at the end of the transplantation
procedure or a sham operation (vessel dissection without
transplantation) was done.
To test the effects of a longer cold ischemia time, we
performed additional experiments on three groups of Lewis
rats. We increased the length of cold ischemia time to two
hours. This time increase necessitated our resorting to an
isograft, rather than an autograft approach. We were not
able to conduct general anesthesia for five hours in these
rats. Thus, separate Lewis donor and recipient rats were
prepared. The donors had a kidney removed, which was
prepared as described above, with the exception that the
cold ischemia time was increased to two hours. The donors
were treated with sense ODN, reverse sense ODN and
vehicle as described above. During the cold ischemia, fresh
recipient rats were prepared. These rats underwent trans-
plantation and bilateral nephrectomy as described above.
Renal function
Twenty-four hours postoperatively, anesthesia with Inac-
tin (Byk Gulden, Konstanz, Germany) i.p. and Ketavet (35
mg/kg) i.m. was induced and cannulas were placed into the
left jugular vein for infusions, into the transplant ureter for
urine collection, and into the femoral artery for the blood
sampling. Rats were placed on a heated surgical table and
the rectal temperature was maintained at 37°C. Infusion
solutions for the measurement of the glomerular filtration
rate (GFR) by inulin clearance were 4% inulin and 1%
bovine albumin (Sigma Chemical Co.) in 0.9% NaCl at a
rate of 50 ml/min per 100 g body wt, as previously described
[36]. After one hour of infusion equilibration, urine and
plasma samples were collected in four 15-minute intervals.
Inulin concentrations in urine and plasma aliquots were
obtained using the standard macroanthrone and colorimet-
ric methods [36].
Western blotting
The excised kidneys were cut into the tissue slices. The
tissue slices were treated with ice cold buffer (10 mM
Tris-HCl, pH 7.4, 100 mM NaCl, 300 mM sucrose, 1 mM
EDTA, 0.2 mM PMSF, 1 mg/ml leupeptin, 0.5% Triton
X-100, 0.2% NaN3) and immediately homogenized. The
homogenate was then spun at 13,000 3 g for five minutes
and the supernatant was collected. After determination of
protein content, the immunoblotting was carried out as
previously published [22]. Briefly, 25 mg of each sample
were run on a 10% polyacrylamide gel and electro-blotted
onto a Poly-Screen PVDF Transfer Membrane (NEN,
Boston, MA, USA). The membrane was then treated
according to a commercially available protocol (Serva,
Heidelberg, Germany). The membrane was incubated with
a monoclonal antibody directed against rat ICAM-1 (clone
1A29; Medac, Hamburg, Germany), followed by a goat
antimouse antibody, linked to alkaline phosphatase (Di-
anova, Hamburg, Germany). After equilibration of the blot
in assay buffer (pH 10.0), the detection was carried out by
incubation with the AP-substrate CDP Star (Serva, Heidel-
berg, Germany) for five minutes. Dot blot and densitome-
try were used for quantitation of ICAM-1 expression. Each
0.1 mg sample was dotted onto a Poly-Screen PVDF
Transfer-Membrane. Further treatment of the membrane
was performed according to the above described protocol
(Serva). The signal was quantified densitometrically with a
Biorad (Freiburg, Germany) video densitometer 620. The
signals were then integrated and the results were expressed
in arbitrary units.
Immunohistochemistry and histopathology
Immunohistochemistry was carried out as previously
described [22]. For immunohistochemical staining, the sec-
tions were incubated with the monoclonal antibody anti-rat
ICAM-1, clone 1A29, (Medac, Hamburg, Germany), mono-
clonal antibody-anti-rat monocytes, clone ED-1 (Camon,
Wiesbaden, Germany), monoclonal antibody anti-rat neu-
trophils, clone His 48, (Dianova, Hamburg, Germany),
monoclonal antibody antibody OX-3 to MHC class II and
diluted in RPMI (Seromed, Heidelberg, Germany) for 30
minutes at room temperature in a humid chamber. After
washing with TBS, the sections were incubated with a
rabbit anti-mouse bridging antibody (Dako, Hamburg,
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Germany). The immunoreactivity was visualized with an
alkaline phosphatase antialkaline phosphatase (APAAP)
complex (Dako). For detection and development we used
the neufuchsin-naphthol-As-Bi-phosphate substrate (Merck,
Darmstadt, Germany) as described.
Semiquantitative data on the ICAM-1 expression were
obtained by measuring the gray values of the film photomi-
crographs using the microdensitometrical program of the
IBAS 2.5 (Kontron, Konstanz, Germany) according to a
previously published microdensitometric method [22]. The
photomicrographs were digitized directly via a television
camera (CCD 72/MTi-camera) on a screen, allowing the
measurement of an entire section at once. Transmissions,
as well as optical densities, were obtained utilizing post-
processing programs.
The degree of leukocyte infiltration was determined by
Fig. 2. Effect of saline treatment, antisense ODN treatment, and reverse
ODN treatment on ICAM-1 expression in transplanted rat kidneys.
Upper panel shows immunohistochemical staining (representative of 30
photomicrographs) for ICAM-1 in sham-operated animals (A), autotrans-
planted animals with saline treatment (B), antisense ODN treatment (C),
and reverse ODN treatment (D). (E) The densitometric data from these
sections (N 5 30, *P , 0.05). Ischemia-reperfusion injury induced a
marked increase in ICAM-1 expression in the glomeruli, along the
endothelial cell lining of the blood vessels, and in the peritubular area.
Antisense ODN prevented the ischemia-induced increase in ICAM-1
expression both in the glomeruli and in the vasculature, while reverse
ODN had no effect.
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visually counting the stained neutrophils and monocytes
respectively in the perivascular and glomerular areas across
kidney sections, as described previously [22]. To quantify
the results, we used the following grading scale: 0 5 no
infiltrating cells were present; 1 5 1 to 4 infiltrating
leukocytes; and 2 5 infiltrates of 5 or more cells. The
infiltrates were expressed as % of the vessels analyzed.
Kidneys from six animals in each group were used for this
purpose. Multiple sections were examined, so that at least
50 separate vessels and glomeruli were evaluated from each
of the four groups.
Six half kidneys from each group were sectioned, fixed in
formalin, and stained with hematoxylin and eosin as de-
scribed for our laboratory previously [22]. Without knowl-
edge of the regimens, sections from each kidney were
evaluated by a pathologist. Tubular necrosis was assessed
with a quantitative grading scale (0 to 3) corresponding to
none, mild, moderate, or severe necrosis as outlined else-
where [22]. Cell swelling, vacuolization, nuclear pyknosis,
necrosis and cellular infiltrate were evaluated.
Statistical analysis
Statistical analysis was carried out on a Macintosh II
computer (Apple Inc., Cupertino, CA, USA) with a com-
mercially available program (Statview; Cricket Software
Inc., Philadelphia, PA, USA). The results (mean 6 SEM)
represent duplicate measurements made on seven to ten
separate rats from each group. Group comparisons were
initially conducted by a Kruskal Wallis analysis. Nonpara-
metric (Wilcoxon test) and parametric (2 way ANOVA)
were used as appropriate. P # 0.05 was considered signif-
icant.
Fig. 3. (A) Western blot for ICAM-1
expression in the kidneys (representative
experiment of 12 kidneys in each group) of
sham operated animals, autotransplanted
animals with saline treatment, antisense ODN
treatment, and reverse ODN treatment. (B)
Densitometric data from these Western blots
(N 5 4 in each group). Ischemia and
reperfusion induced a marked increase in
ICAM-1 expression both in the renal cortex and
in the renal medulla. Treatment with antisense
ODN prevented the ischemia-induced increase
in ICAM-1 expression. *P , 0.01, both in the
vasculature and in the peritubular area. Reverse
ODN had no effect.
Fig. 4. Effect of antisense and reverse ODN on glomerular filtration rate
(GFR). Inulin clearance 24 hours after transplantation (Tx) is shown.
Saline-treated (N 5 4) and reverse ODN-treated animals (N 5 6) were
anuric. Antisense ODN treatment prevented the ischemia-induced acute
renal failure; inulin clearance of these animals (N 5 6) was not different
from sham-operated (N 5 4) renal function control animals. Symbols are:
(f) antisense ODN 1 Tx; (u) reverse ODN 1 Tx; (M) sham operated 1
0.9% NaCl; (s) 0.9% NaCl 1 Tx.
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RESULTS
We first analyzed whether or not donor treatment with
antisense ODN for ICAM-1 down-regulated the target
protein. Figure 2 shows the effect of reverse and antisense
ODN on ICAM-1 expression in transplanted rat kidneys 24
hours after transplantation. In the upper panel are shown
the immunohistochemical staining photomicrographs (rep-
resentative of 30 photomicrographs) for ICAM-1 in sham-
operated animals (Fig. 2A), autotransplanted animals with
saline treatment (Fig. 2B), antisense ODN treatment (Fig.
2C), and reverse ODN treatment (Fig. 2D). Ischemia-
reperfusion injury induced a marked increase in ICAM-1
expression in the glomeruli, along the endothelial cell lining
of the blood vessels, and in the peritubular area. Antisense
ODN treatment prevented the ischemia-induced increase
in ICAM-1 expression, both in the glomeruli and in the
vasculature. In contrast, reverse ODN had no effect. In the
lower panel is shown the densitometric analysis from these
sections (N 5 30, *P , 0.05).
The immunohistochemical results were confirmed by
Western blot analysis of homogenized renal tissue. These
data are shown in Figure 3. Figure 3A shows a Western blot
for ICAM-1 expression in kidneys (representative experi-
ment of 4 kidneys in each group) from sham operated
animals, saline-treated autotransplanted animals, antisense
ODN treated animals, and reverse ODN treated animals.
The effects of sham operation was variable. In some sham
operated animals, ICAM-1 expression was detectable, pre-
sumably as a result of anesthesia and manipulation alone.
Ischemia and reperfusion induced a marked increase in
ICAM-1 expression in the transplanted kidneys. Treatment
with antisense ODN prevented the ischemia-induced in-
crease in ICAM-1 expression. Reverse ODN had no effect.
In the lower panel the densitometric analysis from these
Western blots is demonstrated (N 5 4 in each group, *P ,
0.01).
We then assessed the effect of antisense ODN treatment
on transplant function. Figure 4 illustrates the effect of
antisense ODN and reverse ODN on renal function, and
Figure 4A shows inulin clearance 24 hours after transplan-
tation. Saline-treated and reverse ODN-treated animals
were anuric at 24 hours. Antisense ODN prevented the
ischemia-induced renal failure, and inulin clearance in the
antisense ODN-treated group was not different from sham-
operated animals. Since anuric rats had an effective GFR
of zero, we relied on serum creatinine measurements to
compare the renal function of all groups statistically.
Figure 5 shows serum creatinine concentrations before
and after transplantation. Saline-treated autotransplanted
animals showed a significant increase in creatinine concen-
trations at 12 and 24 hours. Antisense ODN prevented the
ischemia-induced increase in creatinine concentration. Re-
verse ODN had no effect; the creatinine concentrations of
reverse ODN-treated rats were not different from saline-
treated animals.
We studied the effect of antisense ODN treatment on
leukocyte infiltration in transplanted kidneys. Figure 6
shows the immunohistochemical staining (representative of
30 photomicrographs) of transplanted kidneys for neutro-
phils in sham-operated animals (Fig. 6A), autotransplanted
animals with saline treatment (Fig. 6B), antisense ODN
treatment (Fig. 6C), and reverse ODN treatment (Fig. 6D).
We observed a massive granulocytic infiltration in the
glomeruli and, to a lesser extent, in the peritubular area.
The lower panel shows the number of neutrophil infiltrates
in the glomeruli (left) and the perivascular area (right),
qualitatively expressed as no infiltrates, 1 to 4 infiltrates,
or $ 5 infiltrates from these immunohistochemical sections
(vessels counted n.50; P , 0.05). Antisense ODN for
ICAM-1 decreased granulocyte infiltration (P , 0.05).
The monocyte infiltration in transplanted kidneys is
shown in Figure 7. Immunohistochemical staining (repre-
sentative of 30 photomicrographs) of transplanted kidneys
is shown for monocytes in sham-operated animals (Fig.
7A), autotransplanted animals with saline treatment (Fig.
7B), antisense ODN treatment (Fig. 7C), and reverse ODN
treatment (Fig. 7D). In contrast to neutrophil infiltration,
monocytes were observed in lesser numbers and were
mostly seen in the perivascular area. The lower panel shows
the number of monocyte infiltrates in the glomeruli (left)
and the perivascular area (right), qualitatively expressed as
no infiltrates, 1 to 4 infiltrates, or $ 5 infiltrates from these
immunohistochemical sections (vessels counted N . 50;
Fig. 5. Serum creatinine concentrations before and after transplantation
(Tx). Saline-treated animals showed a significant increase in serum
creatinine concentrations after 12 and 24 hours. Antisense ODN treat-
ment prevented the ischemia-induced increase in serum creatinine con-
centrations 12 (*P , 0.01) and 24 hours after Tx (#P , 0.001). Reverse
ODN had no effect. Symbols are: (F) antisense 1 Tx; (M) reverse 1 Tx;
(L) NaCl 1 Tx; () sham operated 1 NaCl.
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Fig. 7. (Opposite page, bottom)
Immunohistochemical staining (representative
of 30 photomicrographs) of transplanted
kidneys for monocytes in sham-operated
animals (A), autotransplanted animals with
saline treatment (B), antisense ODN treatment
(C), and reverse ODN treatment (D). The
number of moncyte infiltrates in the glomeruli
(E) and the perivascular area (F) are
qualitatively expressed as no infiltrates (M), 1
to 4 infiltrates (o), or $ 5 infiltrates (f) from
these immunohistochemical sections (glomeruli
and vessels counted N . 50; *P , 0.05).
Antisense ODN decreased monocyte
infiltration.
Fig. 6. (Opposite page, top)
Immunohistochemical staining (representative
of 30 photomicrographs) of transplanted
kidneys for neutrophils in sham-operated
animals (A), autotransplanted animals with
saline treatment (B), antisense ODN treatment
(C), and reverse ODN treatment (D). The
number of granulocyte infiltrates in the
glomeruli (E) and the perivascular area (F)
qualitatively expressed as no infiltrates (M), 1
to 4 infiltrates (o), or $ 5 infiltrates (f) from
these immunohistochemical sections (glomeruli
and vessels counted N . 50; *P , 0.05).
Antisense ODN treatment decreased neutrophil
infiltration.
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P , 0.05). Antisense ODN treatment decreased monocyte
infiltration significantly.
We then addressed the question of whether or not
immunological markers are induced during reperfusion
injury and whether or not antisense ODN treatment for
ICAM-1 had a beneficial effect. Figure 8 shows the immu-
nohistochemical staining (representative of 30 photomicro-
graphs) of transplanted kidneys for MHC II expression in
sham-operated animals (Fig. 8A), autotransplanted ani-
mals with saline treatment (Fig. 8B), antisense ODN
treatment (Fig. 8C), and reverse ODN treatment (Fig. 8D).
Antisense ODN prevented MHC II expression after isch-
emia reperfusion almost completely.
Finally, we assessed the effect of antisense ODN treat-
ment on reperfusion-induced tissue damage. Figure 9
shows hematoxylin and eosin-stained thin sections of fixed,
paraffin-embedded, transplanted rat kidneys. Sham-oper-
ated animals (Fig. 9A), autotransplanted animals with
saline treatment (Fig. 9B), antisense ODN treatment (Fig.
9C), and reverse ODN treatment (Fig. 9D) are shown
(representative of 30 sections). Inflammatory infiltrate and
tubular necrosis manifested by swollen, vacuolated, proxi-
mal tubular cells with pyknotic nuclei were diminished by
antisense ODN treatment. A quantitative grading scale (6
kidneys from each group) verified these findings (P , 0.05);
saline-treated rats had 2.3 (range 2 to 3), antisense ODN-
treated rats had 1.2 (range 1 to 2), and reverse ODN-
treated rats had 2.4 (range 2 to 3).
Three vehicle treated, three antisense ODN-treated, and
seven reverse sense ODN-treated rats underwent isograft
renal transplantation with two hours of cold ischemia time,
rather than the 30 minutes we applied above in the
autotransplantation experiments. ICAM-1 expression from
vehicle treated kidneys and reverse sense ODN-treated
kidneys was similar, while those from antisense ODN-
treated kidneys showed a 30% decrease in ICAM-1 expres-
sion. Inulin clearance values 24 hours after transplantation
from these three groups were 0.05 6 0.001, 0.2 6 0.05, and
0.35 6 0.06 ml/min/g kidney wt, respectively. In these
experiments the antisense ODN-treated group differed
signifcantly from vehicle treatment, while reverse sense
ODN-treated rats were intermediate. The histological eval-
uation of these kidneys corresponded to the renal function
measurements.
DISCUSSION
We used antisense ODN treatment for ICAM-1 in
transplanted kidneys to test the hypothesis that inhibition
of this adhesion molecule ameliorates the effects of isch-
emia-reperfusion injury in a renal transplantation model.
To only investigate the effects of ischemia and reperfusion
injury and to rule out possible confounding immunological
reactions, we relied on an autotransplantation protocol.
The antisense ODN treatment ameliorated ischemia-reper-
fusion injury, prevented delayed graft function, and de-
creased the expression of immunological marker. Our
results demonstrate that ICAM-1 plays an important role in
mediating ischemia-reperfusion injury and that targeting
this molecule could have a therapeutic effect in organ
transplantation.
We showed earlier that antisense ODN treatment for
ICAM-1 decreased ischemia-induced renal injury and re-
stored renal function in a model of acute renal failure [22].
Other investigators have also shown that ICAM-1 plays an
important role in cell-to-cell adhesion and can ameliorate
ischemia-reperfusion injury in several animal models [23,
27, 29, 30, 37–39]. Recently, Kelly et al demonstrated that
ICAM-1-deficient mice are protected against the effects of
ischemia [40]. Since ICAM-1 plays a role in mediating
immunological response in T-lymphocytes, most investiga-
tors have explored the role of ICAM-1 in acute rejection
[41–46]. Light microscopy studies have demonstrated
heightened ICAM-1 expression in renal allograft rejection
in experimental animals and in humans [46]. Administra-
tion of ICAM-1 blocking antibodies has been shown to
prolong graft survival in nonhuman primates [41]. Haug et
al recently demonstrated in a phase I clinical trial that
anti-ICAM-1-antibody administration was associated with
significantly less delayed graft function and rejection [43].
The ligand to ICAM-1, the leukocyte function-associated
antigen-1, has also been tested in preliminary clinical trials
with encouraging results [47]. However, in renal transplan-
tation the direct effect of ICAM-1 blockade on ischemia-
reperfusion injury and delayed graft function has received
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Fig. 8. Immunohistochemical staining (representative of 30 photomicrographs) of transplanted kidneys for MHC II expression in sham-operated
animals (A), autotransplanted animals with saline treatment (B), antisense ODN treatment (C), and reverse ODN treatment (D). Antisense ODN
prevented ischemia reperfusion induced increase in MHC II expression.
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Fig. 9. Hematoxylin and eosin-stained, thin sections of fixed, paraffin-embedded, rat kidneys (representative of 30 sections) in sham-operated animals
(A), autotransplanted animals with saline treatment (B), antisense ODN treatment (C), and reverse ODN treatment (D). Inflammatory infiltrate and
tubular necrosis manifest by swollen, vacuolated, proximal tubular cells with pyknotic nuclei and necrotic cells was diminished by antisense ODN
treatment.
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less attention. DeMeesters et al recently showed that
ICAM-1 antibodies can reduce reperfusion injury in the
transplanted rat lung [48]. A therapeutic role for ICAM-1
inhibition in preventing ischemia-reperfusion injury is also
suggested in a recent report by Stokes et al [49].
Clinical studies in kidney and liver transplantation have
suggested that poor early function is associated with in-
creased graft loss due to chronic rejection. Ischemia-
reperfusion injury may contribute to rejection by enhancing
graft immunogenicity [50]. We observed an up-regulation
of MHC class II molecules in the control-treated trans-
planted kidneys, as well as an increased infiltration of
immune competent lymphocytes in our study. Ischemic
injury may induce the up-regulation of MHC class II
antigen expression through the local release of cytokines
[51]. That ischemic tissue injury leads to a significant
increases in MHC expression has also been shown by
Waddell et al [52]. Thus, an increase in graft MHC
expression may enhance immunogenicity and increase the
rejection response [51–53]. In addition to alloantigen-
dependent events, antigen-independent factors can influ-
ence chronic rejection of organ allografts. The initial graft
injury, including early ischemia and acute rejection, may
contribute to this process. Tullius et al have shown that
antigen-independent functional and morphologic changes
occur in long-term renal isografts that resemble those in
chronically rejected allografts [35, 54]. An increased ex-
pression of ICAM-1 on the vascular endothelium seems to
play an important mechanistic role [55, 56]. Whether or not
treatment with antisense ODN for ICAM-1 during isch-
emia and reperfusion results in enhanced long-term graft
survival and in decreased chronic rejection is presently
under investigation.
We believe that the antisense approach to ischemia-
reperfusion injury in the grafted kidney could have clinical
utility. Delayed graft function from ischemia and reperfu-
sion injury is a major post-transplant problem, engenders
prolonged hospitalization, expensive hemodialysis treat-
ments, and has a direct negative impact on long-term graft
survival [50]. It is possible to envision preoperative anti-
sense ODN treatment in transplant donors. However, we
believe an immediate infusion of explanted kidneys would
be more practical in transplant medicine. Cadaveric donor
kidneys are routinely stored in preservation solutions for 12
to 48 hours before transplantation. Incubation of these
organs with antisense ODN could result in a significant
down-regulation of the adhesion molecules and prevent
reperfusion injury. Our approach could alter the preserva-
tion procedures of cadaveric organs [7]. We believe that
antisense ODN treatment is particularly appealing because
the treatment is not subject to the same immunological
problems which accompany the use of antibodies directed
against adhesion molecules [32]. We performed a limited
number of isograft transplantations in Lewis rats, to assure
ourselves that lengthening the cold ischemia time would
not change the basic results. Antisense ODN treatment
again ameliorated reperfusion injury, although reverse
sense ODN treatment also appeared to have some protec-
tive effect. We have no direct explanation for this finding,
although nonspecific effects of ODN are possible.
The cadaveric transplant situation lends itself to treat-
ment either of the donor or donor renal graft ex vivo.
Treating the former may be inefficient and expensive, while
treating the latter may be inefficient because of rapid organ
cooling. An ideal gene transfer vehicle for organ preserva-
tion must be highly efficient and rapid. We have not yet
established the ideal gene transfer vehicle, however, the
cationic lipid preparation, lipofectin, was used in this study
and in our earlier investigation [22]. With this approach we
were able to deliver antisense ODN and decreased the
ICAM-1 expression in the reperfused kidney by about 50%
when rats were treated six hours prior to transplantation.
Currently we are evaluating liposomes with recombinant
viral fusion proteins as a more rapid and efficient gene
transfer approach.
We did not show that antisense ODN treatment im-
proves long-term renal allograft survival in this study. Nor
have we shown that treatment of the graft ex vivo and
subsequently subjecting the graft to cold storage will be
effective, although our data suggest that two hours of cold
ischemia gives results similar to the shorter 30-minute cold
ischemia time. More studies remain to be done. Further-
more, we are aware of limitations in our study and view the
results with caution. We performed a histological grading
scale and quantitative Western analysis to give objective
results. Histological sections were presented, which admit-
tedly were not selected in a random fashion. We have
assumed that the ODN-related effects were all related to
an action within the kidney, although in the autotransplan-
tation experiments, an action elsewhere in the body (on
inflammatory cells, for example) may have contributed.
However, we have demonstrated that we can ameliorate
ischemia-reperfusion injury in a model of renal transplan-
tation with antisense ODN treatment for ICAM-1. Our
findings shed light on the role of ICAM-1 in mediating
ischemia-reperfusion injury and give cause for optimism in
terms of developing a novel, therapeutic approach to
improve patient outcome after renal transplantation.
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APPENDIX
Abbreviations used in this manuscript are: APAAP, alkaline phospha-
tase antialkaline; GFR, glomerular filtration rate; ICAM, intercellular
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adhesion molecule; LEW RT, Lewis rat; LFA-1, lymphocyte function-
associated antigen-1; i.p., intraperitoneally; i.v., intravenously; ODN,
oligodesoxynucleotides; UW, University of Wisconsin.
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